Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03832946




Registration number
NCT03832946
Ethics application status
Date submitted
4/02/2019
Date registered
6/02/2019
Date last updated
22/05/2024

Titles & IDs
Public title
A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Scientific title
A Randomized, 52 Week, Double-blind, Multicentre, Parallel, Placebo-controlled Phase 2b Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Investigating the Efficacy and Safety of GB0139, an Inhaled Galectin-3 Inhibitor.
Secondary ID [1] 0 0
2018-002664-73
Secondary ID [2] 0 0
GALACTIC-1
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis (IPF) 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GB0139
Treatment: Drugs - Placebo

Experimental: A. GB0139 3 mg once a day - Inhalation of GB0139

Placebo Comparator: B. Placebo once a day - Inhalation of Placebo


Treatment: Drugs: GB0139
GB0139 is a galectin-3 inhibitor designed to modulate the fibrogenic response to tissue injury. It is administered as inhalation once a day.

Treatment: Drugs: Placebo
Placebo is administered as inhalation once a day
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annual Rate of Decline in Forced Vital Capacity (FVC)
Timepoint [1] 0 0
52 weeks
Secondary outcome [1] 0 0
Number of Participants With Respiratory Related Hospitalizations
Timepoint [1] 0 0
52 weeks
Secondary outcome [2] 0 0
Assessment of Respiratory Related Quality of Life Using the St. George's Respiratory Questionnaire (SGRQ)
Timepoint [2] 0 0
52 weeks

Eligibility
Key inclusion criteria
1. Male and female subjects aged = 40 years of age with a diagnosis of IPF established
during the previous five years according to ATS/ERS/Fleischner criteria.

2. Lung function parameters as follows:

1. Forced Vital Capacity (FVC) > 45% of the predicted value at screening

2. Diffusion lung capacity for carbon monoxide (DLCO) (corrected for Hb) of 30% to
79% of the predicted value at screening

3. Subjects who currently are not being treated with nintedanib or pirfenidone; or cannot
tolerate nintedanib or pirfenidone

4. Subjects must sign and date a written, IRB/EC approved informed consent form and any
required authorization prior to initiation of any study procedures.
Minimum age
40 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Currently has significant airways obstruction: Forced Expiratory Volume in 1 s
(FEV1)/Forced Vital Capacity (FVC) ratio of < 0.7 at screening.

2. Has clinical evidence of active infection, including, but not limited to, bronchitis,
pneumonia, sinusitis, urinary tract infection, and cellulitis.

3. Has a history of malignancy within the last 2 years with the exception of basal cell
carcinoma, chronic lymphocytic leukaemia (under observation) and prostate cancer
requiring anti-androgens, localised treatment (minor surgery, radiotherapy) and/or
managed by observation.

4. Has any condition other than IPF that, in the opinion of the investigator, is likely
to result in the death of the subject within the next 2 years.

5. Presence of other disease that may interfere with testing procedures or in the
judgement of the Investigator may interfere with trial participation or may put the
patient at risk when participating in this trial.

6. Is likely to receive lung transplantation within the next 12 months.

7. Currently receiving nintedanib, pirfenidone, high dose corticosteroid, cytotoxic
(e.g., chlorambucil, azathioprine, cyclophosphamide, methotrexate), vasodilator
therapy for pulmonary hypertension (e.g., bosentan). A current dose of less than or
equal to 15 mg/day of prednisone or its equivalent is acceptable if the dose is
anticipated to remain stable during the study.

8. Prior use of GB0139 (also called TD139) or previously randomized in GALACTIC-1.

9. Prior use of nintedanib or pirfenidone within 7 days of initiation of screening.

10. Prior use of investigational drugs within 30 days (or 5 half-lives, whichever is
longer) of initiation of screening.

11. Participating in another clinical trial, either interventional or observational.

12. Has a history of unstable or deteriorating cardiac or pulmonary disease (other than
IPF) within the previous six months, including, but not limited to, the following:

1. Unstable angina pectoris or myocardial infarction, or percutaneous coronary
intervention within the last 6 months

2. Congestive heart failure requiring hospitalization

3. Uncontrolled clinically significant arrhythmias

13. If female, the subject is pregnant or lactating or intending to become pregnant before
participating in this study during the study and within (5 half- lives plus 30 days)
after last dose of the study drug; or intending to donate ova during such time period.

14. Woman considered to be of childbearing potential who do not use highly effective birth
control methods during the study.

15. Hypersensitivity to the active substance (TD139/GB0139) or the excipient (lactose).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
19/02/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
17/05/2023
Sample size
Target
Accrual to date
Final
172
Recruitment in Australia
Recruitment state(s)
QLD,SA,WA
Recruitment hospital [1] 0 0
Lung Research QLD - Chermside
Recruitment hospital [2] 0 0
Flinders Medical Centre - Adelaide
Recruitment hospital [3] 0 0
Respiratory Clinical Trials - Kent Town
Recruitment hospital [4] 0 0
Institute for Respiratory Health Sir Charles Gairdner Hospital - Nedlands
Recruitment hospital [5] 0 0
TrialsWest - Spearwood
Recruitment postcode(s) [1] 0 0
4032 - Chermside
Recruitment postcode(s) [2] 0 0
5042 - Adelaide
Recruitment postcode(s) [3] 0 0
5067 - Kent Town
Recruitment postcode(s) [4] 0 0
6009 - Nedlands
Recruitment postcode(s) [5] 0 0
6163 - Spearwood
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
New Hampshire
Country [14] 0 0
United States of America
State/province [14] 0 0
North Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
Pennsylvania
Country [17] 0 0
United States of America
State/province [17] 0 0
Tennessee
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
United States of America
State/province [19] 0 0
Utah
Country [20] 0 0
United States of America
State/province [20] 0 0
Virginia
Country [21] 0 0
United States of America
State/province [21] 0 0
Wisconsin
Country [22] 0 0
Belgium
State/province [22] 0 0
Wallon Region
Country [23] 0 0
Belgium
State/province [23] 0 0
Antwerp
Country [24] 0 0
Belgium
State/province [24] 0 0
Brussels
Country [25] 0 0
Belgium
State/province [25] 0 0
Namur
Country [26] 0 0
Canada
State/province [26] 0 0
Ontario
Country [27] 0 0
Canada
State/province [27] 0 0
Toronto
Country [28] 0 0
France
State/province [28] 0 0
Bobigny
Country [29] 0 0
France
State/province [29] 0 0
Lille
Country [30] 0 0
France
State/province [30] 0 0
Marseille
Country [31] 0 0
France
State/province [31] 0 0
Paris
Country [32] 0 0
France
State/province [32] 0 0
Rennes
Country [33] 0 0
France
State/province [33] 0 0
Saint Pierre
Country [34] 0 0
France
State/province [34] 0 0
Saint-Pierre
Country [35] 0 0
France
State/province [35] 0 0
Strasbourg
Country [36] 0 0
France
State/province [36] 0 0
Tours
Country [37] 0 0
Georgia
State/province [37] 0 0
Tbilisi
Country [38] 0 0
Germany
State/province [38] 0 0
Baden-Württemberg
Country [39] 0 0
Germany
State/province [39] 0 0
Hessen
Country [40] 0 0
Germany
State/province [40] 0 0
Rhine-Westphalia
Country [41] 0 0
Germany
State/province [41] 0 0
Sachsen
Country [42] 0 0
Germany
State/province [42] 0 0
Saxony
Country [43] 0 0
Germany
State/province [43] 0 0
Bamberg
Country [44] 0 0
Germany
State/province [44] 0 0
Donaustauf
Country [45] 0 0
Germany
State/province [45] 0 0
Essen
Country [46] 0 0
Germany
State/province [46] 0 0
Leipzig
Country [47] 0 0
Germany
State/province [47] 0 0
Munich
Country [48] 0 0
Ireland
State/province [48] 0 0
Dublin
Country [49] 0 0
Israel
State/province [49] 0 0
Jerusalem
Country [50] 0 0
Israel
State/province [50] 0 0
Kefar Sava
Country [51] 0 0
Israel
State/province [51] 0 0
Petah Tikva
Country [52] 0 0
Israel
State/province [52] 0 0
Ramat Gan
Country [53] 0 0
Israel
State/province [53] 0 0
Re?ovot
Country [54] 0 0
Italy
State/province [54] 0 0
Catania
Country [55] 0 0
Italy
State/province [55] 0 0
Milan
Country [56] 0 0
Italy
State/province [56] 0 0
MIlan
Country [57] 0 0
Italy
State/province [57] 0 0
Modena
Country [58] 0 0
Italy
State/province [58] 0 0
Napoli
Country [59] 0 0
Italy
State/province [59] 0 0
Padova
Country [60] 0 0
Italy
State/province [60] 0 0
Palermo
Country [61] 0 0
Italy
State/province [61] 0 0
Siena
Country [62] 0 0
Italy
State/province [62] 0 0
Turin
Country [63] 0 0
Poland
State/province [63] 0 0
Lodz
Country [64] 0 0
Poland
State/province [64] 0 0
Mazovia
Country [65] 0 0
Poland
State/province [65] 0 0
Malopolskie
Country [66] 0 0
Poland
State/province [66] 0 0
Pomerania
Country [67] 0 0
Poland
State/province [67] 0 0
Poznan
Country [68] 0 0
Russian Federation
State/province [68] 0 0
Chelyabinsk
Country [69] 0 0
Russian Federation
State/province [69] 0 0
Kazan
Country [70] 0 0
Russian Federation
State/province [70] 0 0
Moscow
Country [71] 0 0
Russian Federation
State/province [71] 0 0
Saint Petersburg
Country [72] 0 0
Russian Federation
State/province [72] 0 0
Yaroslavl
Country [73] 0 0
Russian Federation
State/province [73] 0 0
Yekaterinburg
Country [74] 0 0
Spain
State/province [74] 0 0
Asturias
Country [75] 0 0
Spain
State/province [75] 0 0
Cantabria
Country [76] 0 0
Spain
State/province [76] 0 0
Galicia
Country [77] 0 0
Spain
State/province [77] 0 0
Madrid
Country [78] 0 0
Spain
State/province [78] 0 0
Barcelona
Country [79] 0 0
Spain
State/province [79] 0 0
Valencia
Country [80] 0 0
Ukraine
State/province [80] 0 0
Chernivtsi
Country [81] 0 0
Ukraine
State/province [81] 0 0
Kyiv
Country [82] 0 0
Ukraine
State/province [82] 0 0
Ternopil
Country [83] 0 0
Ukraine
State/province [83] 0 0
Vinnytsya
Country [84] 0 0
United Kingdom
State/province [84] 0 0
Cambridgeshire
Country [85] 0 0
United Kingdom
State/province [85] 0 0
Devon
Country [86] 0 0
United Kingdom
State/province [86] 0 0
Greater London
Country [87] 0 0
United Kingdom
State/province [87] 0 0
Greater Manchester
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Hampshire
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Leicestershire
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Merseyside
Country [91] 0 0
United Kingdom
State/province [91] 0 0
Newcastle
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Nottinghamshire
Country [93] 0 0
United Kingdom
State/province [93] 0 0
South Yorkshire
Country [94] 0 0
United Kingdom
State/province [94] 0 0
West Midlands
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Bristol
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Edinburgh

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Galecto Biotech AB
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Syneos Health
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/Industry
Name [2] 0 0
bioRASI, LLC
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF
(idiopathic pulmonary fibrosis) investigating the efficacy and safety of GB0139.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03832946
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Toby Maher, MD, PhD
Address 0 0
Keck Medicine of USC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03832946